Interleukin-17 (IL-17) has been proved to be involved in the pathogenesis of several autoimmune diseases, including lupus, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. The regulation of IL-17 signal transduction is less studied. miR-30a has been identified to be downregulated in these human autoimmune diseases and their related animal models. However, how it functions in IL-17-mediated inflammation and the pathogenesis of these diseases remain unknown. In this study, we showed that miR-30a inhibits IL-17-mediated NF-κB and MAPK activation, leading to the reduced production of inflammatory cytokines and chemokines. miR-30a also reduced mRNA stability triggered by IL-17 stimulation. These suppressive effects of miR-30a were mediated by directly targeting Traf3ip2 mRNA (coding for Act1). Thus, we concluded that the downregulation of miR-30a in autoimmune diseases may exacerbate IL-17-mediated inflammation, which may serve as a potential target for the therapy of these diseases.
Get full access to this article
View all access options for this article.
References
1.
BartelDP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116:281–297.
2.
BrennanFM, McInnesIB. 2008. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest, 118:3537–3545.
3.
CalinGA, LiuCG, SevignaniC, FerracinM, FelliN, DumitruCD, ShimizuM, CimminoA, ZupoS, DonoM, et al.2004. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A, 101:11755–11760.
4.
CobbBS, HertweckA, SmithJ, O'ConnorE, GrafD, CookT, SmaleST, SakaguchiS, LiveseyFJ, FisherAG, MerkenschlagerM. 2006. A role for Dicer in immune regulation. J Exp Med, 203:2519–2527.
5.
CodarriL, FontanaA, BecherB. 2010. Cytokine networks in multiple sclerosis: lost in translation. Curr Opin Neurol, 23:205–211.
CumminsJM, HeY, LearyRJ, PagliariniR, DiazLAJr., SjoblomT, BaradO, BentwichZ, SzafranskaAE, LabourierE, et al.2006. The colorectal microRNAome. Proc Natl Acad Sci U S A, 103:3687–3692.
8.
DongW, ZhuP. 2012. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics. Autoimmun Rev, 11:844–851.
9.
FiresteinGS. 2006. Inhibiting inflammation in rheumatoid arthritis. N Engl J Med, 354:80–82.
10.
GaffenSL. 2009. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol, 9:556–567.
11.
GenoveseMC, Van den BoschF, RobersonSA, BojinS, BiaginiIM, RyanP, Sloan-LancasterJ. 2010. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum, 62:929–939.
12.
GeyerM, Muller-LadnerU. 2010. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol, 22:246–251.
HartupeeJ, LiuC, NovotnyM, SunD, LiX, HamiltonTA. 2009. IL-17 signaling for mRNA stabilization does not require TNF receptor-associated factor 6. J Immunol, 182:1660–1666.
15.
HeJ, LangG, DingS, LiL. 2013. Pathological role of interleukin-17 in poly I:C-induced hepatitis. PLoS One, 8:e73909.
16.
KollsJK, LindenA. 2004. Interleukin-17 family members and inflammation. Immunity, 21:467–476.
17.
KornT, BettelliE, OukkaM, KuchrooVK. 2009. IL-17 and Th17 Cells. Annu Rev Immunol, 27:485–517.
18.
KumarswamyR, MudduluruG, CeppiP, MuppalaS, KozlowskiM, NiklinskiJ, PapottiM, AllgayerH. 2012. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer, 130:2044–2053.
19.
LevinSD. 2009. IL-17 receptor signaling: ubiquitin gets in on the act. Sci Signal, 2:pe64.
20.
LipskyPE, van der HeijdeDM, St ClairEW, FurstDE, BreedveldFC, KaldenJR, SmolenJS, WeismanM, EmeryP, FeldmannM, et al.2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 343:1594–1602.
21.
LiuY, DongJ, MuR, GaoY, TanX, LiY, LiZ, YangG. 2013. MicroRNA-30a promotes B cell hyperactivity in patients with systemic lupus erythematosus by direct interaction with Lyn. Arthritis Rheum, 65:1603–1611.
22.
MaddurMS, MiossecP, KaveriSV, BayryJ. 2012. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol, 181:8–18.
23.
O'ConnellRM, RaoDS, ChaudhuriAA, BaltimoreD. 2010. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol, 10:111–122.
24.
PedersenIM, ChengG, WielandS, VoliniaS, CroceCM, ChisariFV, DavidM. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature, 449:919–922.
25.
QianY, LiuC, HartupeeJ, AltuntasCZ, GulenMF, Jane-WitD, XiaoJ, LuY, GiltiayN, LiuJ, et al.2007. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol, 8:247–256.
SongX, QianY. 2013. The activation and regulation of IL-17 receptor mediated signaling. Cytokine, 62:175–182.
31.
SunD, NovotnyM, BulekK, LiuC, LiX, HamiltonT. 2011. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol, 12:853–860.
32.
TaganovKD, BoldinMP, BaltimoreD. 2007. MicroRNAs and immunity: tiny players in a big field. Immunity, 26:133–137.
33.
VisoneR, PallanteP, VecchioneA, CirombellaR, FerracinM, FerraroA, VoliniaS, ColuzziS, LeoneV, BorboneE, et al.2007. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 26:7590–7595.
ZhaoJJ, LinJ, ZhuD, WangX, BrooksD, ChenM, ChuZB, TakadaK, CiccarelliB, AdminS, et al.2014. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res, 74:1801–1813.
36.
ZhongB, LiuX, WangX, ChangSH, WangA, ReynoldsJM, DongC. 2012. Negative regulation of IL-17-mediated signaling and inflammation by the ubiquitin-specific protease USP25. Nat Immunol, 13:1110–1117.
37.
ZhuH, WuH, LiuX, LiB, ChenY, RenX, LiuCG, YangJM. 2009. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy, 5:816–823.
38.
ZhuS, PanW, ShiP, GaoH, ZhaoF, SongX, LiuY, ZhaoL, LiX, ShiY, QianY. 2010. Modulation of experimental autoimmune encephalomyelitis through TRAF3-mediated suppression of interleukin 17 receptor signaling. J Exp Med, 207:2647–2662.
39.
ZhuS, PanW, SongX, LiuY, ShaoX, TangY, LiangD, HeD, WangH, LiuW, et al.2012. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat Med, 18:1077–1086.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
